Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dentsply SironaXRAY -3.66%55 Debt-to-EBITDA is 9.55 as of Mar. 2026, which is 2481% above its 10-year median of 0.37. GuruFocus rates XRAY with a GF Score™ of 55/100 and a GF Value™ of $19.00 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Dentsply Sirona ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Dentsply Sirona's Debt-to-EBITDA or its related term are showing as below:
XRAY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -53.65 Med: 0.37 Max: 9.23
Current: -18.35
During the past 13 years, the highest Debt-to-EBITDA Ratio of Dentsply Sirona was 9.23. The lowest was -53.65. And the median was 0.37.
XRAY's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs XRAY: -18.35
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Dentsply Sirona Debt-to-EBITDA Related Terms
Dentsply Sirona Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Dentsply Sirona's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XRAY vs LMAT, PLSE, KMTS: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Dentsply Sirona's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dentsply Sirona Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dentsply Sirona's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dentsply Sirona's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Dentsply Sirona (XRAY) has a Debt-to-EBITDA of 9.55 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dentsply Sirona. This is 2481% above median its historical median of 0.37. According to the industry distribution chart, Dentsply Sirona ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Dentsply Sirona's Debt-to-EBITDA too high?
Dentsply Sirona's current Debt-to-EBITDA of 9.55 is 2481% above median its 10-year median of 0.37. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Dentsply Sirona's value of 9.55 is 508.3% above this industry median. Based on the distribution chart, Dentsply Sirona ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Dentsply Sirona has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dentsply Sirona's Debt-to-EBITDA compare to LMAT and PLSE?
According to the Medical Devices & Instruments industry distribution chart, Dentsply Sirona ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Dentsply Sirona in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Dentsply Sirona's value of 9.55 is 508.3% above this benchmark. While the company's 10-year median is 0.37 vs. the industry median of 1.57, Dentsply Sirona has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dentsply Sirona's current Debt-to-EBITDA of 9.55 is 508.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dentsply Sirona. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dentsply Sirona's current Debt-to-EBITDA is 9.55, which is 2481% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dentsply Sirona stock overvalued right now?
Based on GuruFocus' analysis, Dentsply Sirona (XRAY) is currently considered Possible Value Trap. The stock's GF Value™ is $19.00, compared to a current price of $13.16 — trading 30.8% below its estimated fair value. The current Debt-to-EBITDA is 9.55, which is 2481% above median its 10-year median of 0.37 and 508.3% above the Medical Devices & Instruments industry median of 1.57. Dentsply Sirona's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Dentsply Sirona (XRAY), the current Debt-to-EBITDA is 9.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dentsply Sirona (XRAY) Overvalued in 2026?
Based on GuruFocus' analysis, Dentsply Sirona stock appears to be undervalued.
The current stock price of $13.16 is trading 30.8% below its estimated GF Value™ of $19.00.
GuruFocus considers Dentsply Sirona to be Possible Value Trap.
Key valuation signals for XRAY:
Debt-to-EBITDA: 9.55 (2481% above median its 10-year median of 0.37)
GF Value™: $19.00 vs. price of $13.16 (30.8% below fair value)
Industry Position: 508.3% above the Medical Devices & Instruments median (#999999 of 467)
No single metric tells the full story. See the XRAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
55GF Score
Get the complete analysis for XRAY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XRAY has been successfully added to your 
